Back to results
US 12,419,964 B2Granted
Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload
AssigneesEli Lilly and Company, Universite D'Aix-Marseille, Inserm (Institut National De La Sante Et De La Recherche Medicale), Institut Jean Paoli & Irene Calmettes, Centre National de la Recherche Scientifique (CNRS), Mablink Bioscience, Universite Claude Bernard Lyon
InventorsJacobus Petrus Maria Elands, Joanna Fares, Guy Fournet, Benoit Joseph, Florence Lhospice, Marc Lopez, Daniel Olive, Xavier Preville, Warren Viricel
Life of this patent
Estimating the term…
Abstract
The present disclosure provides Nectin-4 antibody drug conjugates (ADCs) comprising exatecan and pharmaceutical compositions thereof, and methods of using the ADCs for the treatment of cancer.
Claims11
An antibody-drug conjugate (ADC) of the formula:
- wherein:
- Ab is an antibody that binds human Nectin-4 and comprises a heavy chain (HC) and a light chain (LC), wherein:
- Ab comprises a HC of SEQ ID NO:5 and a LC of SEQ ID NO:6, DAR is 8, and the Ab is conjugated via cysteines at positions C222, C228, C231 of the HC and via a cysteine of C214 of the LC.
Dependencies are inferred from the claim text.